Carfilzomib: Preliminary Phase I/II data

Preliminary data from 19 evaluable patients with newly diagnosed multiple myeloma (MM) in the dose-escalation Phase I portion of an ongoing Phase I/II trial showed that IV carfilzomib plus Revlimid lenalidomide and dexamethasone produced a partial response or better in 100% of patients, a very good partial response or better in 63% of patients, and a complete or near-complete response in 37% of patients after a median of 4 months of treatment. A single dose-limiting toxicity (DLT) of non-febrile neutropenia occurred at the 27 mg/m 2 dose and the MTD has not yet been reached. Data will be presented at the American Society of Hematology meeting in Orlando in December. ...